Fact checked by Jennifer Klump Key Takeaways Insulin costs have declined over the past two years, and additional price cuts ...

Sanofi (Euronext: SAN; NYSE: SNY) announced today that it received FDA approval for its Toujeo Max SoloStar insulin pen, the highest capacity long-acting insulin pen that will be available on the ...

Amid consumer angst and political pressure over the cost of life-saving insulin, Sanofi announced Thursday it would slash the price of its most-prescribed insulin, Lantus. Sanofi said it will cut the ...

Feb. 27 -- THURSDAY, Feb. 26 (HealthDay News) -- Sanofi-Aventis's Apidra (insulin glulisine) Solostar injection pen has been approved to treat diabetes, the company said Thursday in a news release.

The world's three premier makers of insulin are reducing prices like never before. In a span of less than three weeks, Eli Lilly, Novo Nordisk and Sanofi—in that order—have announced price cuts to ...

Credit: Getty Images. Rezvoglar may now be substituted for Lantus at the pharmacy counter without the need for an intervention from the prescriber. The Food and Drug Administration (FDA) has approved ...

Basaglar (insulin glargine) and Lantus (insulin glargine) are brand-name prescription medications. They’re approved by the Food and Drug Administration (FDA) to: improve blood sugar levels in adults ...

(Reuters) - U.S. generics drugmaker Mylan said on Thursday that the United States Patent and Trademark Office had rejected Sanofi's infringement claims relating to insulin drug Lantus. Sanofi is ...

Lannett is one step closer to launching biosimilar insulin glargine. Recently, the company completed subject dosing in the pivotal clinical trial of biosimilar insulin glargine, a product being ...

COPENHAGEN, July 17 (Reuters) - Denmark's Novo Nordisk , the world's biggest insulin maker, is suing rival Sanofi-Aventis for breach of a U.S. patent on a dose delivery system, a company spokesman ...